Classen — A Guide For Post-Prometheus Patent Claims

Law360, New York (July 30, 2012, 1:57 PM EDT) -- In the wake of the U.S. Supreme Court’s decision in Mayo Collaborative Services v. Prometheus Laboratories Inc., 132 S.Ct. 1289 (2012), the 35 U.S.C. § 101 threshold for patentability of claims to medical diagnostic methods is still a bit murky. It is clear that an active step is required and that the active step must be something more than a “well-understood, routine, conventional activity previously engaged in by scientists who work in the field.” Id at 1291.

But, to date, no post-Prometheus decision has provided biotechnology...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.